Home
NICE Guidance
Published Guidance

Adalimumab for the treatment of moderate to severe ulcerative colitis

Technology appraisal [TA262] Published date: 25 July 2012

Guidance

This guidance has been updated and replaced by NICE technology appraisal guidance 329.

About NICE
Into practice
News
Contact us
Leave feedback
Jobs

Newsletters and alerts
Blog
Twitter
YouTube
Facebook
LinkedIn

Explore

Guidance
Pathways
Standards and indicators
Savings and productivity
Evidence search
BNF
BNFC
Clinical knowledge summaries
Journals and databases

Reusing our content

Reuse information
NICE UK Open Content Licence

Guidance app

Android
iOS

Get involved

Register as a stakeholder
Citizens council
Consultations
Fellows and scholars
Join a committee
Meetings in public
Student champions
Tenders
Public involvement

Accessibility
Freedom of information
Syndication services
Glossary
Terms and conditions

Copyright © 2017 National Institute for Health and Care Excellence. All rights reserved.